Clasado Biosciences (‘Clasado’), a global leader in the development of clinically proven prebiotic ingredient and product solutions for the human gut microbiome, has announced that its award-winning galactooligosaccharide (GOS) ingredient, Bimuno® – already the most studied prebiotic of its kind – has now reached a new landmark figure in studies.

The ingredient is now supported by over 100 scientific studies into its safety and efficacy, including more than 20 clinical trials. The landmark represents the latest stage in the research path of Bimuno, which is found in supplement and functional food applications around the globe. 

Originating as a research project at the University of Reading, Bimuno has been shaped and developed over a 17-year journey. Today, it is one of the most studied commercially available prebiotic ingredients available to brands and formulators. With the publishing of the latest studies, the scientific evidence behind its safety and efficacy has reached the triple digit landmark.

Dr Lucien Harthoorn, Research & Development Director at Clasado Biosciences, commented: “We have often highlighted how Bimuno is the most studied prebiotic ingredient of its kind, but it’s sometimes difficult to visualise just what this looks like, and the amount of effort that goes into achieving this kind of efficacy. At Clasado, we’re proud to have one of the most accomplished research and development divisions, which help us to develop the ingredient technology to ensure it’s always delivering the results that consumers are looking for, as well as helping to build a stronger pool of shared knowledge when it comes to gut health. 

“It’s no secret that today’s consumer is more proactive and engaged with their health and wellbeing, which naturally puts gut health at the forefront of discussion. Key areas such as immune support and mental health are surging up in the agenda. In developing a focused and targeted prebiotic that suits a wide range of product applications, we’re arming brands with the tools for commercial success.”

Bimuno is a prebiotic GOS ingredient that selectively nourishes bifidobacteria, a type of beneficial bacterium in the gut associated with important areas of health and wellbeing. Bimuno is available in powder and syrup formats, with an extremely low clinically effective dose. 

Per Rehné, CEO at Clasado Biosciences, concluded: “Our role as a true leader in our field is to never rest on laurels – we must always be pushing the prebiotic category forwards to affect real global change. Clasado is a business with a clear mission, our work certainly doesn’t end here. We’ve surpassed the 100-study milestone in efficacy and safety, and we look forward to continuing our scientific work, impacting human health through the gut microbiome.

For more information about Clasado Biosciences and its award-winning prebiotic GOS ingredient Bimuno, visit www.clasado.com